Last reviewed · How we verify

NCT04977765

Cardiometabolic Health in Transgender Males

Active, enrolled Last updated 3 October 2025
What this trial tests

trial in Transgender in 90 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline
30 September 2021
Primary endpoint
31 March 2027
1 August 2027

Quick facts

Lead sponsorMedical College of Wisconsin
StatusActive, enrolled
Study typeOBSERVATIONAL
Enrollment90
Start date30 September 2021
Primary completion31 March 2027
Estimated completion1 August 2027
Sites1 location across United States

Conditions studied

Sponsor

Medical College of Wisconsin

Who can join

Adults 12 to 30, any sex, with Transgender or Transgenderism. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Transgender individuals are those with a gender identity opposite the sex they were assigned at birth. Approximately 1% of the population is transgender, equating to \~60,000 transgender Wisconsinites. A transgender boy or man is someone with a 46,XX karyotype and typical female genitalia but a male gender identity and desire for more male-typical gender expression. Gender-affirming testosterone (hormonal) treatment (GAHT) is the cornerstone of masculinizing therapy for transgender men and boys, resulting in estrogen (E2) suppression and circulating testosterone (T) levels equivalent to cisgender males. Historically, GAHT was initiated after an E2-driven puberty, but the last decade has seen an explosion of referrals for GAHT in transboys, many of whom are exposed to only low E2 levels before puberty is halted with blocker therapy. Knowledge of risks incurred by GAHT rely on low-quality studies, precluding conclusive assessment of GAHT's long-term impact on cardiometabolic outcomes. Data on transboys receiving GAHT before completion of E2-driven puberty are sparser and no studies have addressed mechanisms by which GAHT may affect vascular physiology. The investigators aim to determine the cardiometabolic impact of GAHT in transboys/men and to determine if any differences identified are mechanistically dependent on the timing of GAHT relative to puberty.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Transgender

Currently open trials in the same condition.

Other Medical College of Wisconsin trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04977765.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing